| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2006;114:992-999.)
© 2006 American Heart Association, Inc.
Arrhythmia/Electrophysiology |
From the Departments of Pharmacology (A.B., A.N.P., I.S., P.D., Y.K., I.S.C., R.B.R., M.R.R.) and Pediatrics (M.R.R.), Center for Molecular Therapeutics, Columbia University, New York, NY; Guidant Corporation, St Paul, Minn (J.Q., B.K., S.G.); and Departments of Physiology and Biophysics, Institute of Molecular Cardiology, State University of New York at Stony Brook (Z.L., H.L., Z.P., I.P., I.S.C., P.R.B., M.R.R.).
Correspondence to Michael R. Rosen, MD, Center for Molecular Therapeutics, College of Physicians and Surgeons of Columbia University, 630 W 168 St, PH7West-321, New York, NY 10032. E-mail mrr1{at}columbia.edu
Received February 6, 2006; revision received June 5, 2006; accepted June 9, 2006.
Background Biological pacemakers (BPM) implanted in canine left bundle branch function competitively with electronic pacemakers (EPM). We hypothesized that BPM engineered with the use of mE324A mutant murine HCN2 (mHCN2) genes would improve function over mHCN2 and that BPM/EPM tandems confer advantage over either approach alone.
Methods and Results In cultured neonatal rat myocytes, activation midpoint was 46.9 mV in mE324A versus 66.1 mV in mHCN2 (P<0.05). mE324A manifested a positive shift of voltage dependence of gating kinetics of activation and deactivation compared with mHCN2 (P<0.05) in myocytes as well as Xenopus oocytes. In intact dogs in complete atrioventricular block, saline (control), mHCN2, or mE324A virus was injected into left bundle branch, and EPM were implanted (VVI 45 bpm). Twenty-fourhour ECGs were monitored for 14 days. With EPM discontinued, there was no difference in duration of overdrive suppression among groups. However, basal heart rates in controls were less than those in mHCN2, which did not differ from those in E324A (45 versus 57 versus 53 bpm; P<0.05). When spontaneous rate fell below 45 bpm, EPM intervened at that rate, triggering 83% of beats in control, contrasting (P<0.05) with 26% (mHCN2) and 36% (mE324A). On day 14, epinephrine (1 µg/kg per minute IV) induced a 50% heart rate increase in all mE324A, one third of mHCN2, and one fifth of control (P<0.05 mE324A versus control or mHCN2).
Conclusions mE324A induces faster, more positive pacemaker current activation than mHCN2 and stable, catecholamine-sensitive rhythms in situ that compete with EPM comparably but more catecholamine responsively than mHCN2. BPM/EPM tandems function reliably, reduce the number of EPM beats, and confer sympathetic responsiveness to the tandem.
This article has been cited by other articles:
![]() |
M. E. Mangoni and J. Nargeot Genesis and Regulation of the Heart Automaticity Physiol Rev, July 1, 2008; 88(3): 919 - 982. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Rosen, P. R. Brink, I. S. Cohen, and R. B. Robinson Cardiac Pacing: From Biological to Electronic ... to Biological? Circ Arrhythmia Electrophysiol, April 1, 2008; 1(1): 54 - 61. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. Plotnikov, I. Shlapakova, M. J. Szabolcs, P. Danilo Jr, B. H. Lorell, I. A. Potapova, Z. Lu, A. B. Rosen, R. T. Mathias, P. R. Brink, et al. Xenografted Adult Human Mesenchymal Stem Cells Provide a Platform for Sustained Biological Pacemaker Function in Canine Heart Circulation, August 14, 2007; 116(7): 706 - 713. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. M.H. Hoogaars, A. Engel, J. F. Brons, A. O. Verkerk, F. J. de Lange, L.Y. E. Wong, M. L. Bakker, D. E. Clout, V. Wakker, P. Barnett, et al. Tbx3 controls the sinoatrial node gene program and imposes pacemaker function on the atria Genes & Dev., May 1, 2007; 21(9): 1098 - 1112. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |